证券代码：688137 证券简称：近岸蛋白 公告编号：2025-023 苏州近岸蛋白质科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监 管指引第1号——规范运作》等相关规定，上述账户将专用于暂时闲置募集资金进行 现金管理的结算，不会用于存放非募集资金或用作其他用途。公司将在产品到期且 无后续使用计划时及时注销以上专户。 二、风险控制措施 1、公司将严格按照《上市公司募集资金监管规则》《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》《上海证券交易所科创板股票上市规则》 等有关规定办理相关现金管理业务。 2、公司按照决策、执行、监督职能相分离的原则建立健全现金管理的审批和执 行程序，有效开展和规范运行现金管理的投资产品购买事宜，确保资金安全。 3、公司将严格遵守审慎投资原则筛选投资对象,主要选择信誉好、规模大、有 能力保障资金安全的发行主体所发行的产品。 4、公司财务部相关人员将及时分析和跟踪投资产品的投向、项目进展情况，如 评估发现存在可能影响公司资金安全的风险因素，将及时采取相应保全措施,控制理 财风险。 本 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-022 苏州近岸蛋白质科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 7 月 26 | 年 | 27 | 日~2025 | 年 | 7 | 月 | 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 40.4337万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.5762% | | | ...

Meeting Overview - The shareholders' meeting of Suzhou Nearshore Protein Technology Co., Ltd. was held on May 29, 2025, at Donghengsheng International Hotel, Suzhou [1] - A total of 56 ordinary shareholders attended the meeting, holding 47,772,421 voting rights, which accounts for 68.47% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with the following voting results: - Proposal 1: 99.8649% approval from ordinary shareholders, with 47,707,900 votes in favor [1] - Proposal 2: 99.8670% approval from ordinary shareholders, with 47,708,900 votes in favor [2] - Proposal 3: 99.8208% approval from ordinary shareholders, with 47,686,815 votes in favor [2] - Proposal 4: 99.8187% approval from ordinary shareholders, with 47,685,815 votes in favor [2] - Proposal 5: 99.8191% approval from ordinary shareholders, with 47,686,015 votes in favor [2] Legal Compliance - The meeting was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association, as confirmed by the attending lawyers [3]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-021 苏州近岸蛋白质科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 29 日 （二） 股东大会召开的地点：苏州市吴江区文苑路 88 号东恒盛国际大酒店五楼 姑苏厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 56 | | --- | --- | | 普通股股东人数 | 56 | | 2、出席会议的股东所持有的表决权数量 | 47,772,421 | | 普通股股东所持有表决权数量 | 47,772,421 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.4702 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.4702 | （ ...

苏州近岸蛋白质科技股份有限公司（以下简称"苏州近岸蛋白"）于2025年5月28日发布股东及董监高减 持股份结果公告，披露了股东南京金溧创业投资合伙企业（有限合伙）（"南京金溧"）和苏州金灵创业 投资合伙企业（有限合伙）（"苏州金灵"）的减持情况。 减持前：两股东为一致行动人，共持股超72万股 减持计划实施前，南京金溧和苏州金灵为一致行动人关系，二者共计持有苏州近岸蛋白728,589股股 份，合计占公司总股本比例为1.0383%。其中，南京金溧持股363,479股，持股比例0.5180%；苏州金灵 持股365,110股，持股比例0.5203%，二者持股均来源于IPO前取得。 减持计划与实施：集中竞价减持近70万股，计划实施完毕 本次实际减持情况与此前披露的减持计划、承诺一致，减持时间区间届满已实施减持，实际减持已达到 减持计划最低减持数量（比例），且未提前终止减持计划。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据 ...

重要内容提示： 本次减持计划实施前，股东南京金溧创业投资合伙企业（有限合伙）（以下 简称"南京金溧"）和苏州金灵创业投资合伙企业（有限合伙）（以下简称"苏 州金灵"）为一致行动人关系，共计持有公司 728,589 股股份，合计占公司总股 本比例为 1.0383% 证券代码：688137 证券简称：近岸蛋白 公告编号：2025-020 股东持有的基本情况 苏州近岸蛋白质科技股份有限公司 股东及董监高减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 减持计划的实施结果情况 公司于 2025 年 2 月 25 日披露了《股东减持股份计划公告》（公告编号： 2025-005），公司股东拟通过集中竞价、大宗交易、协议转让等方式合计减持其 所持有的公司股份合计不超过 728,589 股，减持比例合计不超过公司股份总数的 1.0383%。 2025 年 5 月 26 日，公司收到股东发来的《关于股份减持结果的告知函》， 本次减持股东通过集中竞价交易方式合计减持公司股份 699,478 股，占公司总股 本比例为 ...

Core Viewpoint - The 2024 Annual General Meeting of Suzhou Nearshore Protein Technology Co., Ltd. outlines the procedures and key agenda items for the meeting, emphasizing the importance of shareholder rights and the company's commitment to transparency and governance [1][2][3]. Meeting Procedures - The company has established guidelines for verifying the identity of attendees to ensure that only eligible shareholders participate in the voting process [1]. - Shareholders must arrive at least 30 minutes before the meeting to complete registration and present necessary documentation [1][2]. - The meeting will follow a structured agenda, allowing shareholders to exercise their rights to speak, inquire, and vote on various proposals [2][3]. Voting Mechanism - Voting will be conducted through a combination of on-site and online methods, with results to be announced in a formal resolution [3]. - Shareholders must express their opinions on submitted proposals as either "agree," "disagree," or "abstain," and any improperly filled ballots will be considered as abstentions [3]. Financial Performance - The company reported a net profit attributable to shareholders of -54.4163 million yuan for the year, a decline of 523.68% compared to the previous year [6]. - Total assets at the end of the reporting period were 2.218 billion yuan, reflecting a decrease of 3.51% from the beginning of the year [6]. Board of Directors' Report - The Board of Directors has outlined its work for the year, focusing on enhancing internal controls and governance structures to support sustainable development [6][7]. - The Board has actively engaged in strategic planning and oversight of financial performance, ensuring compliance with relevant laws and regulations [7][8]. Supervisory Committee's Report - The Supervisory Committee has conducted oversight of the company's financial management and compliance with legal requirements, confirming that the company operates within the legal framework [20][21]. - The committee has also reviewed the management of raised funds, ensuring that there are no violations in the use of these funds [20][21]. Future Plans - The company aims to enhance its governance practices and operational efficiency while focusing on cost reduction and improving investor relations [14][15]. - Plans include strengthening internal controls and compliance measures to ensure high-quality development and protect shareholder interests [14][15].

苏州近岸蛋白质科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688137 证券简称：近岸蛋白 苏州近岸蛋白质科技股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 苏州近岸蛋白质科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024 | | 年年度股东大会会议须知 | | 1 | | | --- | --- | --- | --- | --- | --- | | 2024 | | 年年度股东大会会议议程 | | 3 | | | | 议案一 | 关于 2024 | 年年度报告及其摘要的议案 | | 5 | | | 议案二 | 关于 2024 | 年度董事会工作报告的议案 | | 6 | | | 议案三 | 关于 2024 | 年度监事会工作报告的议案 | | 17 | | | 议案四 | 关于 2024 | 年度财务决算报告的议案 | | 23 | | | 议案五 | 关于 2025 | 年度董事薪酬方案的议案 | | 28 | | | 议案六 | 关于 2025 | 年度监事薪酬方案的议案 | | 30 | | | 议案七 | 关于《2024 | 年度利润 ...

Core Viewpoint - The report outlines the ongoing supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. following its IPO on the Sci-Tech Innovation Board, highlighting the company's financial performance, governance, and compliance with regulatory requirements [1][2][3]. Continuous Supervision Work - The sponsoring institution has established a robust supervision system and executed a work plan to ensure compliance with relevant regulations [1]. - Regular communication, site visits, and due diligence have been conducted to monitor the company's operations [1][2]. - The company has faced issues related to unauthorized share reductions by shareholders, leading to public apologies and share repurchases [2][3]. Financial Performance - The company reported a significant decline in net profit, with a loss of 54.42 million yuan, a decrease of 523.68% year-on-year, attributed to macroeconomic conditions and increased operational costs [11][12]. - Revenue for the year was 127.56 million yuan, down 16.73% from the previous year, indicating challenges in market demand and operational efficiency [11][12]. Core Competitiveness - The company has developed 23 core technologies and established seven comprehensive technology platforms, which are crucial for maintaining its competitive edge in the recombinant protein industry [12][13]. - The company emphasizes innovation and has a strong focus on R&D, with R&D expenses accounting for 39.14% of revenue, reflecting a commitment to technological advancement [20]. Industry Risks - The recombinant protein industry is characterized by intense competition and rapid technological changes, which may pose risks to the company's market position if it fails to keep pace with innovations [8][9]. - Regulatory changes and market dynamics, particularly in the mRNA vaccine sector, present uncertainties that could impact the company's sales and operational stability [10]. Governance and Compliance - The company has implemented a comprehensive internal control system and governance structure to ensure compliance with legal and regulatory standards [4][5]. - Continuous monitoring of the company's adherence to commitments and regulatory requirements is a priority for the sponsoring institution [5][6]. Talent and R&D Development - The company has a strong technical team and management, which is essential for sustaining its innovation and competitive advantage [19]. - Ongoing investments in R&D are aimed at enhancing product offerings and expanding market reach, with a focus on mRNA and diagnostic products [13][14].

民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 2024 年度持续督导跟踪报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法（2023 年 2 月修订）》《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 以及《科创板上市公司持续监管办法（试行）》等有关法律法规和规范性文件的 要求，负责近岸蛋白上市后的持续督导工作，并出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 本持续督导期间，保荐机构已建立健全 | | 1 | 度，并针对具体的持续督导工作制定相 | 并有效执行了持续督导制度，并制定了 | | | 应的工作计划 | 相应的工作计划 | | | 根据中国证监会相关规定，在持续督导 工作开始前，与上市公司或相关当事人 | 本持续督导期间，保荐机构已与近岸蛋 | | | | 白签订承销及保荐协议，该协议明确了 | | 2 ...